All news

Relay target trimmed to $27.42, still 52% upside

Alpha Vantage · TradingView · · AI-summarised by FinFlash

Relay Therapeutics, Inc. (RLAY) has seen its average 12-month price target slightly decrease from $27.58 to $27.42, according to 12 analysts, still implying a 52% potential upside from its Nov. 4 closing price. The consensus rating from 13 analysts remains a "Buy," with no Holds or Sells.

Read original source

FDS company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.